Moneycontrol
    Moneycontrol PRO
    FiDEX 2026
    FiDEX 2026
    Trending Topics

    business

    Pharma sector: RBS picks Cipla, Lupin; shuns Dr Reddy's

    Prakash Agarwal, Equity Analyst - India Pharma, RBS is positive on Lupin and advises investor to buy on dips. In the largecap space, Cipla is his top pick He has a target price of Rs 371 on the stock. In the midcap space, he likes Glenmark Pharma.

    first published: Jul 7, 2011 02:04 pm

    LATEST VIDEOS

    Watch More →

    A collection of the most-viewed Moneycontrol videos.

    Watch and Follow our leading shows

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347
    CloseParallel Income Plan 2026